OverviewSuggest Edit

Viatris is a healthcare company. Its portfolio comprises molecules across a range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally-recognized brands, generic, complex generic and branded medicines, a portfolio of biosimilars, and a variety of over-the-counter consumer products. Viatris is a company formed by the combination of Mylan and Upjohn, a division of Pfizer.

TypePublic
Founded2020
HQCanonsburg, PA, US
Websiteviatris.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2020)45,000
Job Openings179
Revenue (FY, 2020)$11.8 B
Share Price (Jun 2021)$15.3(-2%)
Cybersecurity ratingBMore

Key People/Management at Viatris

Robert J. Coury

Robert J. Coury

Executive Chairman
Michael Goettler

Michael Goettler

Chief Executive Officer
Paul Campbell

Paul Campbell

Chief Accounting Officer & Corporate Controller
Rajiv Malik

Rajiv Malik

President
Kristin Dibartolomeo

Kristin Dibartolomeo

Chief of Staff, Office of the CEO
Sanjeev Narula

Sanjeev Narula

Chief Financial Officer
Show more

Viatris Office Locations

Viatris has offices in Canonsburg, Carole Park, Millers Point, Sofia and in 15 other locations
Canonsburg, PA, US (HQ)
1000 Mylan Blvd
Carole Park, AU
15 Garnet St
Millers Point, AU
level 1/30-34 Hickson Rd
Sofia, BG
bul. "Sitnyakovo" 48
Toronto, CA
85 Advance Rd, Etobicoke
Beijing, CN
3 Chaoyangmen N St, Dongcheng Qu
Show all (21)

Viatris Financials and Metrics

Viatris Revenue

Viatris's revenue was reported to be $11.82 b in FY, 2020
USD

Revenue (Q1, 2021)

4.4b

Net income (Q1, 2021)

(1.6b)

EBIT (Q1, 2021)

(266.2m)

Market capitalization (15-Jun-2021)

18.5b

Closing stock price (15-Jun-2021)

15.3

Cash (31-Mar-2021)

806.9m

EV

42.1b
Viatris's current market capitalization is $18.5 b.
Annual
USDFY, 2020

Revenue

11.8b

Cost of goods sold

8.1b

Gross profit

3.7b

Gross profit Margin, %

31%
Quarterly
USDQ1, 2021

Revenue

4.4b

General and administrative expense

1.2b

R&D expense

184.1m

Operating expense total

1.4b
Annual
USDFY, 2020

Total Debt

25.8b
Quarterly
USDQ1, 2021

Cash

806.9m

Prepaid Expenses

2.0b

Inventories

4.9b

Current Assets

12.3b
Annual
USDFY, 2020

Net Income

(669.9m)

Depreciation and Amortization

2.2b

Inventories

(741.9m)

Accounts Payable

(82.7m)
Quarterly
USDQ1, 2021

Depreciation and Amortization

1.4b

Inventories

(203.4m)

Accounts Payable

191.9m

Cash From Operating Activities

848.8m
USDFY, 2020

Revenue/Employee

262.7k
Show all financial metrics

Viatris Operating Metrics

Viatris's Customers was reported to be 60 k in Dec, 2020.
Dec, 2020

Customers

60 k

Manufacturing Facilities

15

Molecules

1.4 k

SKUs Available

30 k
Show all operating metrics

Human Capital Metrics

Embed Graph
Show all human capital metrics

Viatris Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Viatris Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Viatris Online and Social Media Presence

Embed Graph

Viatris News and Updates

Viatris Signs Memorandum of Understanding with The Defeat NCD Partnership at the United Nations Institute for Training and Research (UNITAR)

Reveals initial findings of the Viatris sponsored report at a high-level panel discussion GENEVA and DUBAI, United Arab Emirates, May 27, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and The Defeat-NCD Partnership (DNCD) at The United Nations Institute for Training and Research...

Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

PITTSBURGH and ST. PAUL, Minn., March 8, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic...

Global $4.7 Billion Erectile Dysfunction Market Outlook and Forecast 2021-2026: Major Players are Eli Lilly and Co, VIVUS, Pfizer, Bayer, Boston Scientific, Coloplast, Teva, Viatris, Dong-A Socio

Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Erectile Dysfunction Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global erectile dysfunction is expected to cross $4.7 billion during the period 2021-2026.The global erectile dysfunct…

Viatris stock tumbles to pace S&P 500 losers after downbeat revenue, free cash flow outlooks

Shares of Viatris Inc. tumbled 11.0% in premarket trading, to pace all of the S&P 500's decliners ahead of the open, after the pharmaceutical and health care services company provided a downbeat 2021 revenue outlook, while saying it was initiating a dividend. The company, formed in November th…

Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments

PITTSBURGH, Feb. 22, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced its 2021 financial guidance and reaffirmed its commitment to rapid de-leveraging, to enhancing and growing free cash flows, particularly following the phasing out of one-time and other stand up costs, to...

Pfizer-Mylan combo Viatris to slash up to 9,000 jobs, shutter manufacturing plants in global cost-cutting drive

A little less than a month after Pfizer's Upjohn unit and Mylan successfully merged to create generics business Viatris, the company is already looking at ways to slash costs. Newly minted Viatris Friday laid out detailed plans for a global manufacturing initiative that could put thousands of job…
Show more

Viatris Frequently Asked Questions

  • When was Viatris founded?

    Viatris was founded in 2020.

  • Who are Viatris key executives?

    Viatris's key executives are Robert J. Coury, Michael Goettler and Paul Campbell.

  • How many employees does Viatris have?

    Viatris has 45,000 employees.

  • What is Viatris revenue?

    Latest Viatris annual revenue is $11.8 b.

  • What is Viatris revenue per employee?

    Latest Viatris revenue per employee is $262.7 k.

  • Who are Viatris competitors?

    Competitors of Viatris include Amgen, Sanofi and Teva Pharmaceuticals.

  • Where is Viatris headquarters?

    Viatris headquarters is located at 1000 Mylan Blvd, Canonsburg.

  • Where are Viatris offices?

    Viatris has offices in Canonsburg, Carole Park, Millers Point, Sofia and in 15 other locations.

  • How many offices does Viatris have?

    Viatris has 21 offices.